Sanofi (SNY)

NASDAQ: SNY · USD

$42.2

+0.33 (+0.8%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-05-20

Our latest published analysis: SNY rated Buy

Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$51.2 / share

Potential value

$57.9 / share

Upside to FV

+17.5%

from $42.2

Moat

6.3/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$104.3B
Revenue (ttm)	55.9B
Net income (ttm)	4.5B
EPS (ttm)	$1.82
Shares out	1.2B
P/E (trailing)	23.2x
P/E (forward)	8.4x
Dividend	$2.42 (5.73%)
Volume	2,730,232
Beta	0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 55.9B
Net income (ttm): 4.5B
EPS (ttm): $1.82
P/E (trailing): 23.2x
P/E (forward): 8.4x
Market cap: $104.3B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$40.56B	$41.62B	$44.29B	$46.72B	+4.8%
Gross profit	$28.68B	$28.99B	$31.08B	$33.67B	+5.5%
Operating income	$10.40B	$6.89B	$7.40B	$6.80B	-13.2%
Net income	$8.37B	$5.40B	$5.56B	$7.81B	-2.3%
EPS (diluted)	$2.69	$2.16	$2.30	$3.20	+6.0%
EBITDA	$13.51B	$11.32B	$10.99B	$12.48B	-2.6%
R&D	$6.50B	$6.51B	$7.39B	$7.84B	+6.5%
SG&A	$8.74B	$9.48B	$9.82B	$10.24B	+5.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	持有
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	强力买入
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	买入

Base and Bull scenarios

Bull20%

Price target

$57.92

+33.0% from spot

Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.

Revenue accelerates beyond historical 4.82% CAGR.
Operating margins improve past 20.0%.
Market re-rates equity closer to peer median.

Base60%

Price target

$51.16

+17.5% from spot

Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.

Revenue growth stable at mid single digits (2.5% terminal).
Operating margin maintained at exactly 20.0%.
Terminal multiple capped conservatively at 12.0x.

Sensitivity: Ke × terminal growth

The highlighted base cell is anchored to composite fair-value midpoint ($51.15). It is the reference value for this grid, not a separate standalone fair-value claim.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
6.3%	$61.9	$69.2	$78.4	$89.5	$89.5
7.3%	$51.2	$56.0	$61.9	$69.2	$78.4
8.3%	$43.6	$47.1	$51.2	$56.0	$61.9
9.3%	$38.0	$40.6	$43.6	$47.1	$51.2
10.3%	$33.6	$35.7	$38.0	$40.6	$43.6

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E8.4

P25 n/aP50 n/aP75 n/a

Trailing P/E18.9

P25 n/aP50 n/aP75 n/a

ROE5.7

P25 n/aP50 n/aP75 n/a

ROIC9.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SNY indicators

Market & fundamental data

Available fields

281

Groups with data

Currency

EUR

Showing 281 of 281 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001121404
Company name	Sanofi
Country	France
Country code	US
CUSIP number	80105N105
Earnings date	2026-10-30
Earnings time	bmo
Employees	74,846
Employees change	-8,032
Employees growth	-9.69%
Enterprise value	$120.7B
Exchange	NASDAQ
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
Industry	Drug Manufacturers - General
Is primary listing	No
Is SPAC	No
ISIN number	US80105N1054
Last 10-K release date	2026-02-17
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$101.1B
Market cap category	Large-Cap
Next earnings date	2026-10-30
Options	Yes
Price	$42.22
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SNY
Website	https://www.sanofi.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.02x
Average P/E ratio (10Y)	18.52x
Average P/E ratio (3Y)	18.87x
Average P/E ratio (5Y)	17.73x
Earnings yield	4.3%
EV/Earnings	26.52x
EV/EBIT	10.14x
EV/EBITDA	7.75x
EV/FCF	10.73x
EV/Sales	2.15x
FCF / EV yield	9.32%
FCF yield	11.14%
Forward EV/Sales	2.17x
Forward P/E	8.93x
Forward P/S	1.81x
Graham number	37.83666
Graham upside	-10.36%
Industry forward P/E	18.51x
Industry P/E	35.9x
Lynch fair value	$9.51
Lynch upside	-77.46%
P/(FCF - SBC) ratio	9.28x
P/(OCF - SBC) ratio	7.83x
P/B ratio	1.26x
P/E ratio	23.23x
P/FCF ratio	8.97x
P/OCF ratio	7.61x
P/S ratio	1.79x
Price / tangible book value	9.84x
Price/EBITDA ratio	6.48x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.16%
EBITDA margin	27.68%
Effective tax rate	23.16%
FCF margin	20.52%
Gross margin	73.45%
Operating margin	21.16%
Pretax margin	10.62%
Profit margin	8.09%
Profit per employee	$60,416
Profitable years	26
Revenue per employee	$746,710
ROA	5.09%
ROA (5Y)	4.55%
ROCE	10.66%
ROE	5.71%
ROE (5Y)	8.3%
ROIC	9.12%
ROIC (5Y)	8.98%
SBC / revenue	0.67%
Tax / revenue	2.46%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-55.57%
EPS growth (Q)	-91.2%
EPS growth (QoQ)	-78.75%
EPS growth 10Y	0.16%
EPS growth 3Y	-21.9%
EPS growth 5Y	-6.58%
EPS growth years	2
FCF growth	5.47%
FCF growth (Q)	236.79%
FCF growth (QoQ)	23.47%
FCF growth 3Y	5.42%
FCF growth 5Y	8.11%
Gross profit growth	10.15%
Gross profit growth (Q)	21.54%
Gross profit growth 3Y	3.79%
Gross profit growth 5Y	7.18%
Net income growth	-56.63%
Net income growth (Q)	-91.29%
Net income growth (QoQ)	-78.75%
Net income growth 3Y	-22.84%
Net income growth 5Y	-7.28%
Net income growth years	2
OCF growth	5.56%
OCF growth (Q)	102.46%
OCF growth (QoQ)	75.88%
OCF growth 10Y	3.84%
OCF growth 3Y	4.87%
OCF growth 5Y	7.57%
Operating income growth	10.31%
Operating income growth (Q)	51.11%
Operating income growth 3Y	-1.98%
Operating income growth 5Y	5.14%
Revenue growth	6.96%
Revenue growth (Q)	14.58%
Revenue growth (QoQ)	9.39%
Revenue growth 10Y	3.67%
Revenue growth 3Y	2.04%
Revenue growth 5Y	5.43%
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2B
Depreciation and amortization	$3.6B
EBIT	$11.8B
EBITDA	$15.5B
EPS	$1.82
FCF per share	$9.33
Financing cash flow	$-8.1B
Free cash flow	$11.2B
Free cash flow minus SBC	$10.8B
Gross profit	$41.1B
Income taxes	$1.4B
Investing cash flow	$-15.8B
Net borrowing	$-246.1M
Net cash flow	$-10.3B
Net income	$4.5B
Operating cash flow minus SBC	$12.8B
Operating income	$11.8B
Revenue	$55.9B
Stock-based compensation	$372.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$66.00
Debt / EBITDA	1.71
Debt / equity	0.34
Debt / FCF	2.41
Goodwill	$46.7B
Interest coverage	17.08
Long-term assets	$112.3B
Long-term liabilities	$32.4B
Net cash (debt)	$-19.7B
Net cash / market cap	-19.62%
Net debt / EBITDA	1.27
Net debt / equity	0.25
Net debt / FCF	1.76
Piotroski F-Score	6
Property, plant and equipment	$13.3B
Shareholders' equity	$79.5B
Tangible book value	$10.2B
Tangible book value per share	$8.51
Total assets	$147.4B
Total cash	$7.3B
Total debt	$26.9B
Total liabilities	$68B
WACC	4.99%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.39
Current assets	$35.1B
Current liabilities	$35.6B
Current ratio	0.99
Inventory turnover	1.25
Net working capital	$565.5M
Quick ratio	0.49
Working capital	$-466.1M
Working capital turnover	14.8

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	2.54%
Dividend growth	10.19%
Dividend growth (10Y)	3.82%
Dividend growth (3Y)	8.38%
Dividend growth (5Y)	4.63%
Dividend growth years	2
Dividend payment date	2026-06-03
Dividend payment years	24
Dividend payout frequency	Annual
Dividend per share	$2.42
Dividend yield	5.73%
Ex-dividend date	2026-05-04
FCF payout ratio	25.68%
Last dividend	$2.42
Payout ratio	131.83%
Shareholder yield	8.26%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	13.37%
10Y return CAGR	4.2%
10Y total return	50.82%
150-day SMA	$43.69
15Y price change	12.67%
15Y return CAGR	3.67%
15Y total return	71.74%
1D price change	0.78%
1M price change	2.72%
1M total return	2.72%
1W price change	2.01%
1W total return	2.01%
1Y price change	-17.86%
1Y return CAGR	-14.59%
1Y total return	-14.59%
20-day SMA	$40.56
200-day SMA	$44.36
20Y price change	-3.08%
20Y return CAGR	2.81%
20Y total return	74.06%
3M price change	-4.02%
3M total return	-4.02%
3Y price change	-2.09%
3Y return CAGR	2.67%
3Y total return	8.23%
50-day SMA	$42.28
50-day SMA vs 200-day SMA	50under200
52-week high	$52.68
52-week high date	2025-11-13
52-week low	$39.07
52-week low date	2026-10-13
5Y price change	-14.81%
5Y return CAGR	-0.13%
5Y total return	-0.65%
6M price change	-8%
6M total return	-4.33%
All-time high	$60.12
All-time high date	2025-03-10
All-time low	$22.53
All-time low date	2003-02-13
Average true range (ATR)	$0.79
Average volume	3.5M
Beta (5Y)	0.28
Change from 52-week high	-19.87%
Change from 52-week low	8.05%
Change from all-time high	-29.75%
Change from all-time low	87.44%
Change from open	0.94%
Day's gap	-0.17%
Dollar volume	$115.3M
High price	$42.27
Low price	$41.64
Monthly RSI	40
Open price	$41.82
Position in 52-week range	91.27%
Premarket change	-0.11%
Premarket close	$41.89
Premarket price	$41.84
Premarket volume	10.4K
Previous close	$41.89
Price vs 150-day SMA	-3.35%
Price vs 20-day SMA	4.13%
Price vs 200-day SMA	-4.81%
Price vs 50-day SMA	-0.11%
Relative volume	0.77
RSI	57.47
Sharpe ratio	-0.76
Sharpe ratio (3Y)	-0.15
Sharpe ratio (5Y)	-0.03
Sortino ratio	-0.81
Sortino ratio (3Y)	-0
Sortino ratio (5Y)	0.18
Volume	2.7M
Weekly RSI	45.31
YTD price change	-12.86%
YTD total return	-9.39%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.1B
Float percentage	90.04%
Shares change (QoQ)	-0.63%
Shares change (YoY)	-2.54%
Shares held by insiders	0.02%
Shares held by institutions	43.06%
Shares outstanding	1.2B
Short % of float	1.08%
Short % of shares	0.97%
Short ratio	4.1 days

Deeper analysis on SNY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this SNY report

What is the latest published SNY stock rating?

Sanofi is shown with Buy in the latest published report, analyzed 2026-05-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SNY analysis?

The full latest published report, analyzed 2026-05-20, lives at /stocks/SNY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for SNY?

The latest published report analyzed 2026-05-20 gives SNY a fair value of USD 51 and a potential value of USD 58. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the SNY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuySNY · Fair value $51.2+17.5%

Read full analysis →

Sanofi (SNY)

Our latest published analysis: SNY rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · SNY

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All SNY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SNY

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	7.5
Management	7.3
Balance Sheet	7.0
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	8.5
Competitive Moat	6.3
Earnings Quality	6.0
Capital Efficiency	5.0